Hypothesis

Age‑related heteroplasmic mtDNA single‑nucleotide variants diminish mitochondrial Ca²⁺ handling, which blunts the cytosolic Ca²⁺ spikes needed to activate calcineurin. Reduced calcineurin activity keeps NFATc3 phosphorylated and cytosolic, lowering nuclear NFATc3‑driven miR‑23a transcription. Loss of miR‑23a releases repression of the atrophy E3 ligases atrogin‑1 and MuRF1, accelerating sarcomere breakdown and sarcopenia.

Mechanistic Model

• mtDNA variants impair electron‑transport chain activity, decreasing ATP production and weakening the mitochondrial membrane potential that drives the calcium uniporter (MCU).
• Consequently, mitochondria take up less Ca²⁺ during each contraction, and the amplitude and speed of cytosolic Ca²⁺ transients fall.
• Calcineurin, a Ca²⁺/calmodulin‑dependent phosphatase, receives weaker activation signals, leaving NFATc3 in its phosphorylated, cytoplasmic state [1].
• Nuclear NFATc3 normally promotes transcription of the microRNA miR‑23a; its decline reduces miR‑23a levels.
• miR‑23a binds the 3′‑UTR of atrogin‑1 (Fbxo32) and MuRF1 (Trim63) transcripts, suppressing their translation. When miR‑23a drops, these E3 ligases are derepressed, increasing ubiquitination of contractile proteins and hastening muscle fiber atrophy.
• NFATc4, which is constitutively nuclear in fast‑twitch fibers [2], is not rescued by this pathway, explaining why atrophy affects both fiber types despite divergent basal NFAT localization.

Testable Predictions

1. In muscles from aged mice, the heteroplasmic mtDNA SNV burden will negatively correlate with the peak amplitude of evoked cytosolic Ca²⁺ transients measured with GCaMP.
2. Restoring mitochondrial Ca²⁺ uptake—either by MCU over‑expression or by a pharmacological agonist such as Sprint—will normalize cytosolic Ca²⁺ spikes, increase nuclear NFATc3, raise miR‑23a, and suppress atrogin‑1/MuRF1 even when mtDNA mutation load remains high.
3. Acute cytosolic Ca²⁺ chelation (e.g., BAPTA‑AM) in young adult mice will phenocopy the aged state: decreased nuclear NFATc3, lower miR‑23a, and elevated atrophy‑gene expression.
4. NFATc4 nuclear abundance will stay unchanged across conditions, indicating the atrophy signal is specific to the NFATc3/miR‑23a axis.

Experimental Design

• Model: Generate a knock‑in mouse bearing a pathogenic mtDNA point mutation (e.g., mt‑Co1 p.Gly…) that accumulates heteroplasmy with age.
• Readouts:
  • Cross with a skeletal‑muscle‑specific GCaMP6f line to record in vivo Ca²⁺ transients during treadmill‑evoked contractions.
  • Fractionate muscle lysates to quantify nuclear versus cytosolic NFATc3 by immunoblot.
  • Measure miR‑23a by RT‑qPCR and atrogin‑1/MuRF1 mRNA and protein by qPCR and Western blot.
  • Assess phenotype via fiber cross‑sectional area (histology), grip strength, and endurance testing.
• Interventions:
  • AAV9‑MCU overexpression delivered intravenously at 6 months of age.
  • Parallel group receiving the MCU activator Sprint (10 mg/kg, i.p., three times weekly).
  • Controls receive AAV9‑GFP or vehicle.
• Timeline: Baseline at 6 months, treatment for 4 months, endpoints at 10 months when heteroplasmy is high and sarcopenia accelerates.

Potential Impact

If validated, this hypothesis would reposition mitochondrial genome integrity as an upstream regulator of the calcineurin/NFAT signaling hub that governs muscle homeostasis. It would suggest that preserving mtDNA function—or directly bolstering mitochondrial Ca²⁺ uptake—could prevent the transcriptional cascade that unleashes atrophy‑promoting E3 ligases, offering a complementary strategy to current exercise‑ or drug‑based sarcopenia therapies. Moreover, it provides a clear mechanistic bridge between mitochondrial retrograde signaling and calcium‑dependent transcriptional control, opening avenues for targeting mitonuclear communication in other age‑related tissues.